Focus: DiscGenics is a private biotechnology company focused on spinal stem cell therapies, specifically developing cell-based treatments for degenerative disc disease. The company operates as a pre-revenue biotech with a narrow therapeutic focus in the musculoskeletal/cell therapy space.
Profile data last refreshed 15h ago · AI intelligence enriched 2w ago
Stable — net +1 jobs in 30d
2 added, 1 removed. Backfill posture.
Best suited for mission-driven early-career scientists willing to tolerate startup volatility in exchange for foundational expertise in regenerative medicine.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for DiscGenics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from DiscGenics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles